Ann M. Leen

Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.

Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells.

Adenovirus as an emerging pathogen in immunocompromised patients.

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.

Adenoviral infections in hematopoietic stem cell transplantation.

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Improving T cell therapy for cancer.

Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12.

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale.

Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.

Cytotoxic T lymphocytes as immune-therapy in haematological practice.

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.

Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.

Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.

Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.

Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

How I treat adenovirus in hematopoietic stem cell transplant recipients.

T-cell therapy: the next generation.

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.

Engineered T cells for pancreatic cancer treatment.

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.

Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma.

Oncolytic immunotherapy of advanced solid tumors with a CD40L expressing replicating adenovirus: assessment of safety and immunological responses in patients.